Related Experiment Video
Updated: Jul 16, 2025

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
Published on: July 2, 2013
Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant Pseudomonas aeruginosa
Eric G Romanowski1, Sonya M Mumper1, Hazel Q Shanks1
1Charles T. Campbell Laboratory of Ophthalmic Microbiology, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Purpose:
To test cefiderocol, a siderophore-cephalosporin antibiotic for topical monotherapy treatment of experimental extensively drug resistant (XDR) Pseudomonas aeruginosa keratitis.
Design:
Preclinical study.
Subjects And Controls:
Deidentified P. aeruginosa keratitis isolates, XDR P. aeruginosa from eye drop outbreak, rabbits, saline, cefiderocol 50 mg/ml, ciprofloxacin 0.3%, and tobramycin 14 mg/ml.
Methods Intervention Or Testing:
Cefiderocol antibacterial activity against P. aeruginosa keratitis isolates (n=135) was evaluated by minimum inhibitory concentration (MIC) testing. Ocular toxicity/tolerability and antibacterial efficacy were tested in vivo with experimental rabbit models. Corneal concentrations and stability were assessed using a bioassay.
Main Outcome Measures:
MIC analysis for susceptibility, graded tests for ocular toxicity/tolerability, CFU analysis for bacterial burden, corneal cefiderocol concentrations.
Results:
100% of P. aeruginosa keratitis isolates were susceptible to cefiderocol (n=135), the MIC90 was 0.125 μg/ml including the XDR isolate (MIC = 0.125 μg/ml). Topical cefiderocol 50 mg/ml was minimally toxic to the ocular surface and was well tolerated. For the XDR P. aeruginosa isolate, topical cefiderocol 50 mg/ml, significantly decreased corneal CFU compared to ciprofloxacin 0.3%, tobramycin 14 mg/ml, and saline. In addition, tobramycin 14 mg/ml was more effective than the saline control. Mean cefiderocol corneal concentrations were 191x greater than the MIC90 of the P. aeruginosa keratitis isolates. Refrigerated cefiderocol maintained antimicrobial activity over a one-month period.
Conclusions:
These results demonstrate that cefiderocol is well tolerated on rabbit corneas and is effective against P. aeruginosa keratitis isolates in vitro and was effective in vivo against an XDR isolate in a rabbit keratitis model. Given the recent outbreak of keratitis caused by this XDR P. aeruginosa, cefiderocol is a promising additional antibiotic that should be further evaluated for topical treatment of keratitis caused by antibiotic resistant P. aeruginosa.
Insights
Cefiderocol effectively treated extensively drug-resistant Pseudomonas aeruginosa keratitis in rabbits. This new antibiotic shows promise for topical treatment of resistant bacterial eye infections.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Pharmacology
Background:
- Antibiotic resistance in Pseudomonas aeruginosa poses a significant threat to ocular health.
- Extensively drug-resistant (XDR) P. aeruginosa strains are increasingly prevalent, necessitating novel therapeutic agents.
- Current topical treatments for bacterial keratitis may be limited by resistance patterns.
Approach:
- Evaluated cefiderocol, a siderophore-cephalosporin, for topical monotherapy in experimental P. aeruginosa keratitis.
- Assessed in vitro susceptibility using minimum inhibitory concentration (MIC) testing.
- Determined in vivo efficacy, ocular toxicity, and corneal penetration in a rabbit keratitis model.
Key Points:
- All P. aeruginosa keratitis isolates (n=135) were susceptible to cefiderocol, with a MIC90 of 0.125 μg/ml.
- Topical cefiderocol (50 mg/ml) demonstrated minimal ocular toxicity and was well-tolerated in rabbits.
- Cefiderocol significantly reduced corneal bacterial burden in vivo against an XDR P. aeruginosa isolate compared to ciprofloxacin and tobramycin.
Conclusions:
- Cefiderocol is a well-tolerated and effective topical antibiotic against P. aeruginosa keratitis isolates in vitro and in vivo.
- The drug achieved high corneal concentrations, exceeding the MIC90.
- Cefiderocol represents a promising therapeutic option for managing keratitis caused by antibiotic-resistant P. aeruginosa.
Related Concept Videos
Hand hygiene
Hand washing...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness
Acute Pyelonephritis II: Diagnostic Studies and Management

